JP2023503399A5 - - Google Patents
Info
- Publication number
- JP2023503399A5 JP2023503399A5 JP2022527137A JP2022527137A JP2023503399A5 JP 2023503399 A5 JP2023503399 A5 JP 2023503399A5 JP 2022527137 A JP2022527137 A JP 2022527137A JP 2022527137 A JP2022527137 A JP 2022527137A JP 2023503399 A5 JP2023503399 A5 JP 2023503399A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/120040 | 2019-11-21 | ||
| CN2019120040 | 2019-11-21 | ||
| PCT/CN2020/130003 WO2021098758A1 (en) | 2019-11-21 | 2020-11-19 | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023503399A JP2023503399A (ja) | 2023-01-30 |
| JPWO2021098758A5 JPWO2021098758A5 (https=) | 2023-11-29 |
| JP2023503399A5 true JP2023503399A5 (https=) | 2023-11-29 |
Family
ID=75980301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527137A Pending JP2023503399A (ja) | 2019-11-21 | 2020-11-19 | 抗ｔｉｍ３抗体と組み合わせて抗ｏｘ４０抗体を用いるがんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230002501A1 (https=) |
| EP (1) | EP4061845A4 (https=) |
| JP (1) | JP2023503399A (https=) |
| KR (1) | KR20220103105A (https=) |
| CN (2) | CN118320076A (https=) |
| AU (1) | AU2020387990A1 (https=) |
| BR (1) | BR112022008184A2 (https=) |
| CA (1) | CA3157319A1 (https=) |
| IL (1) | IL293117A (https=) |
| MX (1) | MX2022006149A (https=) |
| WO (1) | WO2021098758A1 (https=) |
| ZA (1) | ZA202204252B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566935B (zh) | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| SMT201800503T1 (it) * | 2013-03-18 | 2018-11-09 | Janssen Pharmaceuticals Inc | Anticorpi anti-cd (ox40) umanizzati e loro usi |
| EP3099717B1 (en) * | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| TN2019000101A1 (en) * | 2015-05-29 | 2020-07-15 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof. |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| US20200079862A1 (en) * | 2015-12-03 | 2020-03-12 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| US11203637B2 (en) * | 2016-08-26 | 2021-12-21 | Beigene, Ltd. | Anti-Tim-3 antibodies and use thereof |
| CN111542544A (zh) * | 2017-11-01 | 2020-08-14 | 百时美施贵宝公司 | 用于治疗癌症的免疫刺激性激动性抗体 |
| CN110092832B (zh) * | 2018-01-29 | 2020-03-31 | 康源博创生物科技(北京)有限公司 | 抗ox40抗体及其用途 |
| CN112566935B (zh) * | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
-
2020
- 2020-11-19 JP JP2022527137A patent/JP2023503399A/ja active Pending
- 2020-11-19 WO PCT/CN2020/130003 patent/WO2021098758A1/en not_active Ceased
- 2020-11-19 BR BR112022008184A patent/BR112022008184A2/pt unknown
- 2020-11-19 AU AU2020387990A patent/AU2020387990A1/en active Pending
- 2020-11-19 KR KR1020227015822A patent/KR20220103105A/ko active Pending
- 2020-11-19 US US17/778,689 patent/US20230002501A1/en not_active Abandoned
- 2020-11-19 IL IL293117A patent/IL293117A/en unknown
- 2020-11-19 CN CN202410292008.3A patent/CN118320076A/zh active Pending
- 2020-11-19 CN CN202080075615.4A patent/CN114641500B/zh active Active
- 2020-11-19 CA CA3157319A patent/CA3157319A1/en active Pending
- 2020-11-19 MX MX2022006149A patent/MX2022006149A/es unknown
- 2020-11-19 EP EP20889435.2A patent/EP4061845A4/en active Pending
-
2022
- 2022-04-14 ZA ZA2022/04252A patent/ZA202204252B/en unknown